EGFR and glioblastoma: In particular, resistance to EGFR inhibition in human glioma cells was attributed to compensatory signaling by IGF-IR (59), and insulin receptor/IGF-IR signaling was shown to confer resistance to Gefitinib in EGFR-dependent glioblastoma, through compensatory AKT activation (24).